ActivBiotics, Inc. Appoints Steven C. Gilman Chairman and CEO
ActivBiotics, Inc. announced that its board of directors has appointed Steven C. Gilman, Ph.D. as chairman and chief executive officer. Dr. Gilman was previously the company's president and chief executive officer.
Dr. Gilman joined ActivBiotics in March 2004 as president and chief executive from Millennium Pharmaceuticals where he held a number of senior leadership roles including Vice President and General Manager, Inflammation, responsible for the inflammation business. Prior to Millennium, he was Group Director of the arthritis, pulmonary, immunology and antibacterial therapeutic areas at Pfizer Global Research and Development. He has also held scientific, business, and academic appointments at Wyeth, Cytogen Corporation, Temple Medical School and Connecticut College. He currently serves on the board of the Massachusetts Biotechnology Council and Nextcea, Inc., an early-stage private company. Dr. Gilman received his PhD and MS degrees in microbiology from Pennsylvania State University and his post-doctoral training at Scripps Clinic and Research Foundation.
Dr. Gilman succeeds Alan W. Dunton, M.D., who resigned as non-executive chairman earlier this year to become the CEO of Panacos Pharmaceuticals.
Organizations
Other news from the department people

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.